Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes a situation where counterparties are already losing something real and ongoing for as long as they do not have what the company provides, and that this loss is visible in their behavior. Key elements: (1) Running meter on the other side: counterparty is currently accumulating loss/cost/forfeited gain that only stops when company delivers. (2) Other side already acting like the meter is running: real current behavior showing urgency. Also, management conveys that this dynamic is generating meaningful business relative to size and contribution largely ahead. We need to scan transcript for such language. Management discusses business model, network effects, customer adoption, etc. But do they describe counterparties (customers) with a running meter? For example, they talk about HRD testing, DEEP-Lung-IV study, CarePath, etc. But the question is: does management describe that their customers/partners are losing money/output/opportunity continuously until they get SOPHiA's solution, and that they are acting with urgency? They mention "land and expand", utilization, etc. But no explicit description of customers suffering losses while waiting. They talk about benefits of their platform, but not about customers paying a cost for delay. There is some mention of biopharma wanting data, but not a running meter. The question asks specifically: "does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS THEY DO NOT HAVE WHAT THIS COMPANY PROVIDES, and that this accumulating loss on the other side is ALREADY VISIBLE in how those parties are behaving toward the company today?" I don't see that. They talk about unmet needs, but not a current accumulating loss. The examples given: "a buyer whose own plant, fleet, site, network, program, or operation cannot run at full value" etc. No such description. They mention "we view the positive reception from the participating sites as a testament to the high level of interest" for DEEP-Lung-IV, but that's not a running meter. They mention that healthcare institutions continue to choose SOPHiA, but that's adoption, not urgency. They mention HRD partnership with AstraZeneca, but no description of loss from lack of HRD testing.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...